Oura Health Inc Confidentially Files for IPO Marking Milestone for Wearable Tech Sector
Trump Pressures Bank of America JPMorgan on Alleged Conservative Debanking
Trump Rejects Iran Counterproposal Prolonging Strait of Hormuz Standoff and Energy Market Volatility
BofA Issues Cautious Assessment on Deckers DECK PostEarnings Outlook
Singapore Targets Faster Private Banking Account Opening to Boost Wealth Hub Status
Goldman Sachs Reportedly Tapped to Lead SpaceX IPO in Potentially Historic Market Debut
HWC Q1 2026 Earnings Modest EPS Beat Amid Stable Operating Environment
HYPR Q1 2026 Earnings Narrower Loss Exceeds Estimates as Commercialization Efforts Continue
BW Q1 2026 Earnings Significant EPS Miss Sends Shares Lower
GIII Q1 2026 Earnings EPS Misses Estimates as Apparel Group Faces Margin Pressure
Silicom Ltd SILC Q1 2026 Earnings EPS Beat Despite Loss Stock Rises on NarrowerThanExpected Loss
KFS Q1 2026 Earnings Reports Net Loss Amid Limited Financial Disclosures
Amylyx Pharmaceuticals AMLX Gains 344 as Biotech Sentiment Lifts Shares
Infobird IFBD Shares Plunge Nearly 20 Testing Critical Support at 080
Forte Biosciences Inc FBRX Edges Lower as Key Support Holds in Focus
LendingTree Holds Above Support After Modest Gain
Saba Capital Income Opportunities Fund II SABA Holds Steady Near Support Amid Low Volatility
Synopsys Appoints Elliott Management Partner Jesse Cohn to Board of Directors
DCBO Q1 2026 Earnings EPS Misses Estimates by a Slim Margin Stock Slips Slightly
Art Technology Acquisition Warrants ARTCW Rally 606 to 035 Testing Key Resistance
HPP Q1 2026 Earnings Surprise Beat on EPS Amid Persistent Office Market Headwinds
OrthoPediatrics Corp KIDS Q1 2026 Earnings NarrowerThanExpected Loss Fails to Lift Shares
Guidewire Software GWRE Q1 2026 Earnings Strong EPS Beat Drives Positive Market Sentiment
KKR Q1 2026 Earnings EPS Beats Estimates Stock Edges Lower
OII Q1 2026 Earnings EPS Surpasses Estimates by 1156
Damora Therapeutics Q1 2026 Earnings WiderThanExpected Loss Despite Stock Gain
OKUR Q1 2026 Earnings Wider EPS Loss Underscores Heavy RD Investment as PreRevenue Biotech Advances Pipeline